Belgium· BE-AMP-SAM660564-00

Sunlenca 300 mg

A lenacapavir product containing lenacapavir sodium, registered in Belgium by Gilead Sciences Ireland UC. The same ATC class is registered in 15 of our 19 countries.

ATC J05AX31

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedSunlenca 300 mgATCJ05AX31REGISTER NO.BE-AMP-SAM660564-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Lenacapavir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AX31 (lenacapavir), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose

Lenacapavir · ATC J05AX31

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lenacapavir costs, country by country.

Normalised to the WHO defined daily dose (0.19 g), the median price runs from $0.45 in France to $511.10 in Switzerland — a ×1140 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Lenacapavir · price per daily dose (0.19 g)

USD · FX 28 Sept 2026

  • CH Switzerland$511.10
  • FR France$0.45
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Lenacapavir Sodium
Manufacturer
Gilead Sciences Ireland UC
Country
Belgium (BE)
ATC code
J05AX31
ATC class
Lenacapavir
Defined daily dose
0.19 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    7746886
  • be_apb
    4613402
    EUR 3204.05

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lenacapavir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lenacapavir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Sunlenca, Yeytuo
  • Liechtenstein · Sunlenca, Yeytuo
  • Norway · Sunlenca, Yeytuo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eb4b180a-0a87-49da-94a4-2dcb5002782a
GET /v1/drugs/eb4b180a-0a87-49da-94a4-2dcb5002782a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Sunlenca 300 mg",
  "name_fr": "Sunlenca 300 mg",
  "name_nl": "Sunlenca 300 mg",
  "amp_code": "SAM660564-00",
  "strengths": [
    "300.0000",
    "300.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Lenacapavir Sodium",
    "Lenacapavir",
    "Mannitol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Lenacapavir",
  "authorisation_numbers": [
    "EU/1/22/1671/001"
  ]
}

See everything about lenacapavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.